| 產品描述： | Tavilermide is a selective, partial agonist of TrkA, or a nerve growth factor (NGF) mimetic. |
| 靶點： |
TrkA;Trkreceptor |
| 體外研究： |
Tavilermide (MIM-D3) is a tyrosine kinase TrkA receptor agonist, which can be used to treat dry eye.Tavilermide is a proteolytically stable, cyclic peptidomimetic that has been shown to be a partial TrkA receptor agonist. Tavilermide demonstrates activities similar to NGF (but does not bind to the p75NTR receptor) and can potentiate the effects of suboptimal concentrations of NGF |
| 參考文獻： |
1. Meerovitch K, et al. Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye. Clin Ophthalmol. 2013;7:1275-85. |
| 溶解性： |
Soluble in NH4OH、H2O |
| 保存條件： |
-20℃ |
| 配置溶液濃度參考： |
|
1mg |
5mg |
10mg |
| 1 mM |
1.723 ml |
8.613 ml |
17.225 ml |
| 5 mM |
0.345 ml |
1.723 ml |
3.445 ml |
| 10 mM |
0.172 ml |
0.861 ml |
1.723 ml |
| 50 mM |
0.034 ml |
0.172 ml |
0.345 ml |
|
| 注意： |
部分產品我司僅能提供部分信息，我司不保證所提供信息的權威性，僅供客戶參考交流研究之用。 |
上海工商
危險品化學品經營許可證（不帶存儲）
營業執照(三證合一)
北京